Shares of Novavax NVAX fell 26.2% on Jul 14, after the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (“PRAC”) updated the product label of Nuvaxovid, the company’s COVID-19 vaccine, to include some potential side effects like severe allergic reactions and skin problems.
Per the safety report, as of Jun 26, 2022, about 216,000 doses of Nuvaxovid have been administered in the European Union, ever since the company secured approval in the region, last December.
..
.. ..
..
.. ..
Shares of Novavax have plunged 63.9% so far this year compared with the industry’s 20.6% decline.
Novavax's (NVAX 2.26%) long wait is over. After multiple delays, the U.S. Food and Drug Administration (FDA) finally granted Emergency Use Authorization (EUA) to the company's COVID-19 vaccine on Wednesday.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.